Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Q2 2020 earnings call dated Aug. 11, 2020 Corporate Participants: Glenn Schulman -- Senior Vice President, Corporate Communications and
Aurinia Pharmaceuticals Inc.
-(AUPH)
XNAS:AUPH
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Q1 2020 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2020 earnings call dated May. 14, 2020 Corporate Participants: Glenn Schulman -- Head of Investor Relations and Corporate Communications
Aurinia Pharmaceuticals (NASDAQ: AUPH): Q4 2019 Earnings Snapshot
-- Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a fourth-quarter 2019 loss of $0.78 per share versus a loss of $0.14 per share expected.
Aurinia Pharmaceuticals (NASDAQ: AUPH): Q3 2019 Earnings Snapshot
-- Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a third-quarter 2019 loss of $0.21 per share versus a loss of $0.15 per share expected.
Aurinia Pharmaceuticals loss narrowed in Q1; AURORA trial on track
Aurinia Pharmaceuticals (NASDAQ:AUPH / TSX:AUP) narrowed its loss in the first quarter. Post the Q1 results, stock rose 2% in the after-market